Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autologous Dendritic Cells Clear all
Terminated Phase 2 Interventional

p53 Vaccine for Ovarian Cancer

NCT00001827
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine, sargramostim, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

NCT03927222
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006113
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent
Biological · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00010127
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Not listed Phase 1 Interventional

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

NCT03743298
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
AV-MEL-1
Drug
Lead sponsor
Aivita Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Irvine, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

NCT00107185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 10, 2026, 11:37 AM EDT
Withdrawn Phase 2 Interventional

Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

NCT02115126
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP2A-loaded conventional DC vaccine, DUK-CPG-001
Biological
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

NCT00082641
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous dendritic cell-adenovirus p53 vaccine
Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 2 Interventional Results available

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

NCT00776295
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Not listed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00004025
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 2 Interventional

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

NCT01067287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

NCT00107159
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 1 Interventional

Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases

NCT00185874
View directory record Official record
Conditions
Liver Cancer
Interventions
Intratumoral Dendritic Cell Immunotherapy, autologous dendritic cells
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1Phase 2 Interventional

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine and Cyclophosphamide
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional Results available

Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma

NCT03615404
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

NCT00683670
View directory record Official record
Conditions
Melanoma
Interventions
cyclophosphamide, Mature dendritic cell vaccine
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

NCT00050323
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Allogeneic DCs and Autologous RCC Tumor Derived Cells
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 10, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

NCT00798629
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Sep 10, 2026, 11:37 AM EDT
Withdrawn Phase 3 Interventional

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

NCT00043212
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dendritic cell immunotherapy
Drug
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Springdale, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

NCT05518032
View directory record Official record
Conditions
Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 10, 2026, 11:37 AM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 10, 2026, 11:37 AM EDT
Terminated Phase 1Phase 2 Interventional

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

NCT04109482
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
MB-102, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 10, 2026, 11:37 AM EDT